{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T13:43:32Z","timestamp":1777470212979,"version":"3.51.4"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Talanta"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.talanta.2017.09.077","type":"journal-article","created":{"date-parts":[[2017,9,30]],"date-time":"2017-09-30T00:33:35Z","timestamp":1506731615000},"page":"552-562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Quality by design approach in the development of an ultra-high-performance liquid chromatography method for Bexsero meningococcal group B vaccine"],"prefix":"10.1016","volume":"178","author":[{"given":"Luca","family":"Nompari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Orlandini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiana","family":"Campa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Rovini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Del Bubba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Furlanetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.talanta.2017.09.077_bib1","series-title":"Vaccine Design-Methods and Protocols- Volume 1: Vaccines for Human Diseases, Volume 1403 of the Series Methods in Molecular Biology","first-page":"41","article-title":"Future challenges for vaccinologists","author":"Thomas","year":"2016"},{"key":"10.1016\/j.talanta.2017.09.077_bib2","series-title":"The Vaccine Book","first-page":"45","article-title":"Vaccine design in the 21st century","author":"Bottomley","year":"2016"},{"key":"10.1016\/j.talanta.2017.09.077_bib3","doi-asserted-by":"crossref","first-page":"V","DOI":"10.1016\/j.coi.2016.07.001","article-title":"Editorial overview: Vaccines: novel technologies for vaccine development","volume":"41","author":"Rappuoli","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.talanta.2017.09.077_bib4","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1097\/01.inf.0000147642.85129.05","article-title":"Global epidemiology of meningococcal disease and vaccine efficacy","volume":"23","author":"Pollard","year":"2004","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.talanta.2017.09.077_bib5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1128\/CMR.19.1.142-164.2006","article-title":"Prospects for vaccine prevention of meningococcal infection","volume":"19","author":"Harrison","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.talanta.2017.09.077_bib6","doi-asserted-by":"crossref","unstructured":"L. J\u00f3dar, I.M. Feavers, D. Salisbury, D.M. Granoff, Development of Vaccines Against Meningococcal Disease, 359, 2002, pp. 1499\u20131508.","DOI":"10.1016\/S0140-6736(02)08416-7"},{"key":"10.1016\/j.talanta.2017.09.077_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1574-6976.2006.00051.x","article-title":"Conquering the meningococcus","volume":"31","author":"Stephens","year":"2007","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.talanta.2017.09.077_bib8","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/00325481.2016.1203238","article-title":"Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba\u00ae)","volume":"128","author":"Gandhi","year":"2016","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.talanta.2017.09.077_bib9","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.vaccine.2008.01.022","article-title":"Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases","volume":"26","author":"Bardotti","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.talanta.2017.09.077_bib10","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.vaccine.2015.11.057","article-title":"Clinical experience with the meningococcal B vaccine, Bexsero(\u00ae): Prospects for reducing the burden of meningococcal serogrup B disease","volume":"34","author":"Watson","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.talanta.2017.09.077_bib11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"EU meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.talanta.2017.09.077_bib12","doi-asserted-by":"crossref","first-page":"B87","DOI":"10.1016\/j.vaccine.2012.01.033","article-title":"The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens","volume":"30","author":"Serruto","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.talanta.2017.09.077_bib13","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing","volume":"287","author":"Pizza","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.talanta.2017.09.077_bib14","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.vaccine.2014.01.011","article-title":"Quantification by LC\u2013MSE of outer membrane vesicle proteins of the Bexsero\u00ae vaccine","volume":"32","author":"Tani","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.talanta.2017.09.077_bib15","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1016\/j.vaccine.2010.05.014","article-title":"Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus","volume":"28","author":"Giuliani","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.talanta.2017.09.077_bib16","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.jinf.2016.04.017","article-title":"Immunisation of the immunocompromised child","volume":"72","author":"Pinto","year":"2016","journal-title":"J. Infect."},{"key":"10.1016\/j.talanta.2017.09.077_bib17","unstructured":"European Medicines Agency. Bexsero Assessment Report. \u3008http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002333\/human_med_001614.jsp&\u3009. (Accessed 3 May 2017)."},{"key":"10.1016\/j.talanta.2017.09.077_bib18","unstructured":"U.S. Food and Drug Administration. Bexsero Product Information. \u3008http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm431374.htm\u3009. (Accessed 3 May 2017)."},{"key":"10.1016\/j.talanta.2017.09.077_bib19","series-title":"Quality by Design for Biopharmaceutical Drug Product Development, Volume 18 of the Series AAPS Advances in the Pharmaceutical Sciences","first-page":"443","article-title":"Applicability of QbD for vaccine drug product development","author":"Chang","year":"2015"},{"key":"10.1016\/j.talanta.2017.09.077_bib20","series-title":"PAT \u2013 A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance","author":"Guidance for Industry","year":"2004"},{"key":"10.1016\/j.talanta.2017.09.077_bib21","unstructured":"ICH Harmonised Tripartite Guideline. Pharmaceutical development Q8(R2), in: Proceedings of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2009."},{"key":"10.1016\/j.talanta.2017.09.077_bib22","unstructured":"ICH Harmonised Tripartite Guideline. Quality risk management Q9, in:\u00a0Proceedings of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2005."},{"key":"10.1016\/j.talanta.2017.09.077_bib23","unstructured":"ICH Harmonised Tripartite Guideline. Pharmaceutical quality systems Q10, in: Proceedings of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2008."},{"key":"10.1016\/j.talanta.2017.09.077_bib24","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1016\/j.vaccine.2014.02.028","article-title":"Implementation of QbD for the development of a vaccine candidate","volume":"32","author":"Haas","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.talanta.2017.09.077_bib25","doi-asserted-by":"crossref","unstructured":"S. Orlandini, S. Pinzauti, S. Furlanetto, Application of Quality by Design to the Development of Analytical Separation Methods, 405, 2013, pp. 443\u2013450.","DOI":"10.1007\/s00216-012-6302-2"},{"key":"10.1016\/j.talanta.2017.09.077_bib26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.trac.2012.09.007","article-title":"Design spaces for analytical methods","volume":"42","author":"Rozet","year":"2013","journal-title":"Trends Anal. Chem."},{"key":"10.1016\/j.talanta.2017.09.077_bib27","series-title":"Quality-by-Design: As Related to Analytical Concepts, Control and Qualification","first-page":"479","author":"Junker","year":"2015"},{"key":"10.1016\/j.talanta.2017.09.077_bib28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jpba.2013.09.026","article-title":"Improvement of a stability-indicating method by quality-by-design versus quality-by-testing: a case of a learning process","volume":"88","author":"Hubert","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2017.09.077_bib29","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1002\/elps.201400472","article-title":"The successful binomium of multivariate strategies and electrophoresis for the Quality by Design separation of a class of drugs: the case of triptans","volume":"36","author":"Pasquini","year":"2015","journal-title":"Electrophoresis"},{"key":"10.1016\/j.talanta.2017.09.077_bib30","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jpba.2011.04.015","article-title":"Expanding the term \u201cDesign Space\u201d in high performance liquid chromatography (I)","volume":"56","author":"Monks","year":"2011","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2017.09.077_bib31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.chroma.2015.12.080","article-title":"A simultaneous determination of related substances by high performance liquid chromatography in a drug product using quality by design approach","volume":"1432","author":"Tol","year":"2016","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.talanta.2017.09.077_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jpba.2015.03.009","article-title":"Development of liquid chromatographic method for the analysis of dabigatran etexilate mesilate and its ten impurities supported by quality-by-design methodology","volume":"111","author":"Pantovi\u0107","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2017.09.077_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jpba.2013.01.032","article-title":"Using an innovative quality-by-design approach for the development of a stability indicating UHPLC method for ebastine in the API and pharmaceutical formulations","volume":"78-79","author":"Schmidt","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2017.09.077_bib34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jpba.2015.07.003","article-title":"Using an innovative combination of quality-by-design and green analytical chemistry approaches for the development of a stability indicating UHPLC method in pharmaceutical products","volume":"115","author":"Bouss\u00e8s","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2017.09.077_bib35","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jpba.2016.04.022","article-title":"Application of analytical quality by design concept for bilastine and degradation impurities determination by hydrophilic interaction liquid chromatographic method","volume":"125","author":"Terzi\u0107","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2017.09.077_bib36","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.chroma.2017.01.090","article-title":", Optimization and validation of a fast supercritical fluid chromatography method for the quantitative determination of vitamin D3 and its related impurities","volume":"1491","author":"Andri","year":"2017","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.talanta.2017.09.077_bib37","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jpba.2016.11.039","article-title":"Quantitative determination of salbutamol sulfate impurities using achiral supercritical fluid chromatography","volume":"134","author":"Dispas","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2017.09.077_bib38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.talanta.2017.01.013","article-title":"One single, fast and robust capillary electrophoresis method for the direct quantification of intact adenovirus particles in upstream and downstream processing samples","volume":"166","author":"van Tricht","year":"2017","journal-title":"Talanta"},{"key":"10.1016\/j.talanta.2017.09.077_bib39","doi-asserted-by":"crossref","first-page":"7637","DOI":"10.1007\/s00216-015-8921-x","article-title":"Fast analysis of glibenclamide and its impurities: quality by design framework in capillary electrophoresis method development","volume":"407","author":"Furlanetto","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.talanta.2017.09.077_bib40","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1002\/elps.201500155","article-title":"Analytical quality by design in pharmaceutical quality assurance: development of a capillary electrophoresis method for the analysis of zolmitriptan and its impurities","volume":"36","author":"Orlandini","year":"2015","journal-title":"Electrophoresis"},{"key":"10.1016\/j.talanta.2017.09.077_bib41","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1002\/elps.201400173","article-title":"Analytical quality by design in the development of a cyclodextrin-modified capillary electrophoresis method for the assay of metformin and its related substances","volume":"35","author":"Orlandini","year":"2014","journal-title":"Electrophoresis"},{"key":"10.1016\/j.talanta.2017.09.077_bib42","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.chroma.2014.12.065","article-title":"Quality by design in the chiral separation strategy for the determination of enantiomeric impurities: development of a capillary electrophoresis method based on dual cyclodextrin systems for the analysis of levosulpiride","volume":"1380","author":"Orlandini","year":"2015","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.talanta.2017.09.077_bib43","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.chroma.2016.06.082","article-title":"Enantioseparation and impurity determination of ambrisentan using cyclodextrin-modified micellar electrokinetic chromatography: visualizing the design space within quality by design framework","volume":"1467","author":"Orlandini","year":"2016","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.talanta.2017.09.077_bib44","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.talanta.2016.07.038","article-title":"Cyclodextrin- and solvent-modified micellar electrokinetic chromatography for the determination of captopril, hydrochlorothiazide and their impurities: a quality by design approach","volume":"160","author":"Pasquini","year":"2016","journal-title":"Talanta"},{"key":"10.1016\/j.talanta.2017.09.077_bib45","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.chroma.2014.02.088","article-title":"An integrated quality by design and mixture-process variable approach in the development of a capillary electrophoresis method for the analysis of almotriptan and its impurities","volume":"1339","author":"Orlandini","year":"2014","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.talanta.2017.09.077_bib46","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.chroma.2016.09.013","article-title":"A comprehensive strategy in the development of a cyclodextrin-modified microemulsion electrokinetic chromatographic method for the assay of diclofenac and its impurities: Mixture-process variable experiments and quality by design","volume":"1466","author":"Orlandini","year":"2016","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.talanta.2017.09.077_bib47","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.talanta.2012.03.064","article-title":"Mixture-process variable approach to optimize a microemulsion electrokinetic chromatography method for the quality control of a nutraceutical based on coenzyme Q10","volume":"97","author":"Piepel","year":"2012","journal-title":"Talanta"},{"key":"10.1016\/j.talanta.2017.09.077_bib48","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jpba.2013.04.014","article-title":"Multivariate optimization of capillary electrophoresis method: a critical review","volume":"87","author":"Orlandini","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2017.09.077_bib49","series-title":"Pharmaceutical Experimental Design","author":"Lewis","year":"1999"},{"key":"10.1016\/j.talanta.2017.09.077_bib50","first-page":"1","article-title":"The business benefits of Quality by Design (QbD)","volume":"32","author":"Kourti","year":"2012","journal-title":"Pharm. Eng."},{"key":"10.1016\/j.talanta.2017.09.077_bib51","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.vaccine.2011.12.066","article-title":"Structural characterisation, stability and antibody recognition of chimeric NHBA-GNA1030: an investigational vaccine component against Neisseria meningitidis","volume":"30","author":"Martino","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.talanta.2017.09.077_bib52","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.vaccine.2009.01.099","article-title":"Structural organization of NadA\u0394351\u2013405, a recombinant MenB vaccine component, by its physico-chemical characterization at drug substance level","volume":"27","author":"Magagnoli","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.talanta.2017.09.077_bib53","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.chroma.2012.06.066","article-title":"Evaluation of recent very efficient wide-pore stationary phases for the reversed-phase separation of proteins","volume":"1252","author":"Fekete","year":"2012","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.talanta.2017.09.077_bib54","unstructured":"LabSolutions Analytical Data System, C191-E016, Shimadzu Corp., 2012. \u3008https:\/\/www.ssi.shimadzu.com\/products\/literature\/cds\/C191-E016.pdf\u3009. (Accessed 3 May 2017)."},{"key":"10.1016\/j.talanta.2017.09.077_bib55","unstructured":"Empower 3, Product Code 720001257EN, Waters Corp. \u3008http:\/\/www.waters.com\/waters\/library.htm?locale=it_IT&cid=10190669&lid=1529289\u3009. (Accessed 3 May 2017)."},{"key":"10.1016\/j.talanta.2017.09.077_bib56","unstructured":"D. Mathieu, J. Nony, R. Phan-Tan-Luu, NEMROD-W, LPRAI sarl, Marseille."},{"key":"10.1016\/j.talanta.2017.09.077_bib57","unstructured":"MODDE v. 10, MKS Umetrics AB, Sweden."},{"key":"10.1016\/j.talanta.2017.09.077_bib58","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.aca.2013.10.005","article-title":"Quality by design approach in the development of a solvent-modified micellar electrokinetic chromatography method: Finding the design space for the determination of amitriptyline and its impurities","volume":"802","author":"Furlanetto","year":"2013","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.talanta.2017.09.077_bib59","unstructured":"ICH Harmonised Tripartite Guideline. Validation of Analytical Procedures: Text and Methodology Q2(R1), in: Proceedings of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2005."},{"key":"10.1016\/j.talanta.2017.09.077_bib60","unstructured":"USP Validation and Verification Expert Panel: G.P Martin, MS (Chair), K.L. Barnett, C. Burgess, P.D. Curry, J. Ermer, G.S. Gratzl, J. P. Hammond, J. Herrmann, E. Kovacs, D.J. LeBlond, R. LoBrutto, A.K. McCasland-Keller, P.L. McGregor, P. Nethercote, A.C. Templeton, D.P. Thomas, M.L.J. Weitzel, H. Pappa, Proposed New USP General Chapter: The Analytical Procedure Lifecycle \u30081220\u3009. \u3008http:\/\/www.usp.org\/sites\/default\/files\/usp_pdf\/EN\/USPNF\/revisions\/s201784.pdf\u3009. (Accessed 3 May 2017)."},{"key":"10.1016\/j.talanta.2017.09.077_bib61","unstructured":"USP Validation and Verification Expert Panel: G.P Martin, MS (Chair), K.L. Barnett, C. Burgess, P.D. Curry, J. Ermer, G.S. Gratzl, J. P. Hammond, J. Herrmann, E. Kovacs, D.J. LeBlond, R. LoBrutto, A.K. McCasland-Keller, P.L. McGregor, P. Nethercote, A.C. Templeton, D.P. Thomas, M.L.J. Weitzel, Lifecycle Management of Analytical Procedures: Method Development, Procedure Performance Qualification, and Procedure Performance Verification. \u3008http:\/\/www.usp.org\/sites\/default\/files\/usp_pdf\/EN\/USPNF\/revisions\/lifecycle_pdf.pdf\u3009. (Accessed 3 May 2017)."},{"key":"10.1016\/j.talanta.2017.09.077_bib62","series-title":"Design of Experiments \u2013 Principles and Applications","author":"Eriksson","year":"2008"},{"key":"10.1016\/j.talanta.2017.09.077_bib63","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.chemolab.2005.04.010","article-title":"Estimation of the uncertainty of indirect measurements from the propagation of distributions by using the Monte-Carlo method: an overview","volume":"79","author":"Herrador","year":"2005","journal-title":"Chemom. Intell. Lab. Syst."}],"container-title":["Talanta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039914017310214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039914017310214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T12:21:10Z","timestamp":1758543670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039914017310214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":63,"alternative-id":["S0039914017310214"],"URL":"https:\/\/doi.org\/10.1016\/j.talanta.2017.09.077","relation":{},"ISSN":["0039-9140"],"issn-type":[{"value":"0039-9140","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality by design approach in the development of an ultra-high-performance liquid chromatography method for Bexsero meningococcal group B vaccine","name":"articletitle","label":"Article Title"},{"value":"Talanta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.talanta.2017.09.077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}